These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16300642)

  • 21. Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid.
    Araujo DM; Hilt DC
    Neuroscience; 1998 Jan; 82(1):117-27. PubMed ID: 9483508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease.
    Sun Z; Xie J; Reiner A
    Exp Neurol; 2002 Jul; 176(1):55-65. PubMed ID: 12093082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists.
    Blum D; Galas MC; Pintor A; Brouillet E; Ledent C; Muller CE; Bantubungi K; Galluzzo M; Gall D; Cuvelier L; Rolland AS; Popoli P; Schiffmann SN
    J Neurosci; 2003 Jun; 23(12):5361-9. PubMed ID: 12832562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation.
    Borlongan CV; Nishino H; Sanberg PR
    Neurosci Res; 1997 Jul; 28(3):185-9. PubMed ID: 9237266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat.
    Brouillet E; Guyot MC; Mittoux V; Altairac S; Condé F; Palfi S; Hantraye P
    J Neurochem; 1998 Feb; 70(2):794-805. PubMed ID: 9453576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.
    Lee ST; Chu K; Park JE; Hong NH; Im WS; Kang L; Han Z; Jung KH; Kim MW; Kim M
    J Neurochem; 2008 Mar; 104(5):1190-200. PubMed ID: 17976163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular targets and therapeutic strategies in Huntington's disease.
    Rego AC; de Almeida LP
    Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):361-81. PubMed ID: 16101555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
    Blum D; Gall D; Galas MC; d'Alcantara P; Bantubungi K; Schiffmann SN
    J Neurosci; 2002 Oct; 22(20):9122-33. PubMed ID: 12388620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain.
    Bizat N; Galas MC; Jacquard C; Boyer F; Hermel JM; Schiffmann SN; Hantraye P; Blum D; Brouillet E
    Neuropharmacology; 2005 Oct; 49(5):695-702. PubMed ID: 15998526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered microRNA regulation in Huntington's disease models.
    Lee ST; Chu K; Im WS; Yoon HJ; Im JY; Park JE; Park KH; Jung KH; Lee SK; Kim M; Roh JK
    Exp Neurol; 2011 Jan; 227(1):172-9. PubMed ID: 21035445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease.
    Lee ST; Park JE; Kim DH; Kim S; Im WS; Kang L; Jung SH; Kim MW; Chu K; Kim M
    Brain Res; 2008 Feb; 1194():130-7. PubMed ID: 18166168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease.
    Palfi S; Ferrante RJ; Brouillet E; Beal MF; Dolan R; Guyot MC; Peschanski M; Hantraye P
    J Neurosci; 1996 May; 16(9):3019-25. PubMed ID: 8622131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease.
    Saydoff JA; Liu LS; Garcia RA; Hu Z; Li D; von Borstel RW
    Brain Res; 2003 Dec; 994(1):44-54. PubMed ID: 14642447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurochemistry and toxin models in Huntington's disease.
    Beal MF
    Curr Opin Neurol; 1994 Dec; 7(6):542-7. PubMed ID: 7866587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
    Keene CD; Rodrigues CM; Eich T; Linehan-Stieers C; Abt A; Kren BT; Steer CJ; Low WC
    Exp Neurol; 2001 Oct; 171(2):351-60. PubMed ID: 11573988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice.
    Oláh J; Klivényi P; Gardián G; Vécsei L; Orosz F; Kovacs GG; Westerhoff HV; Ovádi J
    FEBS J; 2008 Oct; 275(19):4740-55. PubMed ID: 18721135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
    Pandey M; Borah A; Varghese M; Barman PK; Mohanakumar KP; Usha R
    Neurochem Int; 2009 Nov; 55(6):431-7. PubMed ID: 19410615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.
    Rudinskiy N; Kaneko YA; Beesen AA; Gokce O; Régulier E; Déglon N; Luthi-Carter R
    J Neurochem; 2009 Oct; 111(2):460-72. PubMed ID: 19686238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease.
    Saulle E; Gubellini P; Picconi B; Centonze D; Tropepi D; Pisani A; Morari M; Marti M; Rossi L; Papa M; Bernardi G; Calabresi P
    Mol Cell Neurosci; 2004 Jan; 25(1):9-20. PubMed ID: 14962736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.